This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunology, Other  • Viral Infections  • Immunotherapy  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Intralesional immunotherapy employing skin test (recall) antigens derived from mumps, Candida, and Trichophyton is an effective and safe treatment for verruca vulgaris and verruca plana.^1-2 In adults, we have shown individual treated wart response rates of 60% to 74% (saline control, 22%) and complete clearing of uninjected anatomically distinct and distant warts in 49% to 71% (saline control, 16%). In children with treatment-resistant warts (2 modalities), complete response rates were 47% and 34%, respectively.³

Genital warts cause significant morbidity and discomfort. In addition to traditional destructive modalities, genital warts have been successfully treated by imiquimod, a biologic response modifier capable of increasing, among other cytokines, tissue levels of interferon-.⁴ Eradication of all baseline warts is reported in roughly 50% of subjects treated with 5% imiquimod cream. Differences in response rates between women (77%) and men (40%) have been reported.⁵ Intralesional injection of interferon alfa is also approved for the treatment . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION
Mark King, MD; Sandra Marchese Johnson, MD; Thomas D. Horn, MD